We evaluated the risk of recurrence based on co-occurring actionable mutations, the number of co-mutations, EGFR mutation types, and EGFR exon 19 deletion (19-del) subtypes in resected EGFR-mutated lung adenocarcinomas. This evidence concerns the gene EGFR and lung adenocarcinoma.